NeuroSense Therapeutics Ltd. (NRSN)

1.2700 -0.0600 (-4.51%) At close: 04:00PM EDT

NeuroSense Therapeutics Ltd.

Building B
11 HaMenofim Street
Herzliya 4672562
Israel
972 9 799 6183
https://www.neurosense-tx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Yael Barak	VP of Quality & Compliance	N/A	N/A	1970
Ms. Keren Pushett	Head of HR	N/A	N/A	N/A
Mr. Eidan Loushi	C.R.A.	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Corporate governance

NeuroSense Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.